Prescient Therapeutics Shareholder Briefing
In this session, Prescient Therapeutics CEO and MD Steven Yatomi-Clarke discussed:
- Prescient’s diversified portfolio of both later stage and emerging assets for cancer treatment
- Our lead targeted therapy, PTX-100, which is exhibiting promising data in a disease of unmet need
- The potential significance of accelerating clinical development of PTX-100 in an orphan disease
- How our OmniCAR and CellPryme cell therapy platforms allow us to partner with any CAR-T developer, giving us a ‘shovels to the gold rush’ position
Recorded on 9 February 2023 at 11:00am (AEDT)
Featured Speakers
Steven Yatomi-Clarke
CEO and Managing Director
Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.